Last updated: March 21, 2026
What Is the Drug Identified by NDC 42291-0439?
NDC 42291-0439 corresponds to Eptinezumab, marketed as Vyepti by Lundbeck. It is an injectable monoclonal antibody approved for the prevention of migraine in adults. The drug selectively blocks calcitonin gene-related peptide (CGRP), which is involved in migraine pathogenesis.
Market Size and Demand Drivers
Current Market Landscape
The migraine preventive treatment segment is valued at approximately USD 4 billion globally, with a compound annual growth rate (CAGR) of 8-10% over the last five years (IQVIA 2022). CGRP inhibitors account for nearly 60% of this segment, driven by increased diagnosis, unmet needs for patients with frequent migraines, and shifting preferences from oral medications to biologics.
Key Competitors
| Drug |
Manufacturer |
Approval Date |
Route of Administration |
Annual Cost (USD) |
Market Share (2022) |
| Eptinezumab |
Lundbeck |
February 2020 |
Intravenous |
USD 6,500 |
~20% |
| Erenumab |
Amgen |
May 2018 |
Subcutaneous |
USD 7,400 |
~50% |
| Fremanezumab |
Teva |
June 2018 |
Subcutaneous |
USD 6,850 |
~25% |
| Galcanezumab |
Eli Lilly |
September 2018 |
Subcutaneous |
USD 7,500 |
~5% |
Competitive Position
Eptinezumab distinguishes itself by being administered intravenously quarterly, allowing rapid onset of effects, which appeals to patients preferring infusions over injections. Its market share is growing, but it remains behind erenumab, which benefits from a broader prescribing base due to subcutaneous administration and an established presence.
Price Projections
Current Pricing Dynamics
The average wholesale acquisition cost (AWAC) for Eptinezumab is approximately USD 6,500 per dose, with a typical treatment course comprising four doses annually, totaling about USD 26,000 per year.
Factors Influencing Future Prices
- Market Competition: Increased biosimilar or generic competition, once patent exclusivity ends in 2030, could drive prices down.
- Reimbursement Policies: Payer negotiations and formulary placements heavily influence actual prices paid.
- Clinical Value Demonstrations: Positive real-world evidence (RWE) supporting improved efficacy or patient compliance could sustain or increase list prices.
- Inflation and Healthcare Costs: Broader healthcare inflation trends could elevate prices modestly over the next five years.
Price Trends Forecast (2023-2028)
| Year |
Estimated Average Price per Dose (USD) |
Remarks |
| 2023 |
USD 6,500 |
Stable, reflecting current pricing |
| 2024 |
USD 6,350 |
Slight discount erosion possible |
| 2025 |
USD 6,200 |
Competition effects intensify |
| 2026 |
USD 6,000 |
Volume-based discounts increase |
| 2027 |
USD 5,850 |
Biosimilar entry slated for 2030 |
| 2028 |
USD 5,700 |
Continued downward trend |
Prices may fluctuate by ±5-10% annually depending on therapeutic positioning and reimbursement negotiations.
Regulatory and Patent Outlook
- Patent Status: The primary patent is valid until 2030 in key markets, providing exclusivity through that date.
- Regulatory Filings: The drug’s approval in multiple countries supports a stable global demand trajectory.
- Biosimilar Entry: Anticipated post-2030, likely driving price reductions by 20-40%.
Key Market Trends and Opportunities
- Growth in telemedicine may enhance infusion service reach, expanding Eptinezumab’s market.
- Expanded indications, such as treatment in pediatric populations, could increase overall prescribing.
- Competitive landscape shifts with biosimilars will challenge current pricing strategies and market shares.
Key Takeaways
- The global migraine prophylaxis market exceeds USD 4 billion, with CGRP inhibitors representing the majority.
- Eptinezumab holds a ~20% market share, with priorities on infusion convenience and rapid onset.
- Current pricing sits at USD 6,500 per dose, with projections indicating a gradual decline to USD 5,700 by 2028.
- Patent protection secures exclusivity until 2030; biosimilars anticipated thereafter.
- Price sensitivity and payer strategies will significantly influence actual transaction prices.
FAQs
1. How does Eptinezumab’s administration route affect market adoption?
Intravenous delivery appeals to patients seeking rapid effects and less frequent injections. It can limit some market share growth compared to subcutaneous options, unless healthcare infrastructure supports infusion therapy.
2. What are the key factors driving Eptinezumab’s market growth?
Main drivers include increased migraine diagnosis, patient preferences for biologics, and clinician familiarity. The drug’s unique infusion schedule complements existing subcutaneous treatments.
3. How might biosimilar competition impact Eptinezumab prices?
Post-2030 biosimilars could reduce prices by 20-40%. Competitive pressure would likely lead to lower list and reimbursement prices, affecting profit margins and market share.
4. What reimbursement trends could influence future pricing?
Payer negotiations emphasize cost-effectiveness. Demonstrating superior efficacy or patient compliance could support sustained premium pricing.
5. What emerging markets could influence global sales?
Emerging economies with expanding healthcare access and increasing migraine prevalence could represent growth opportunities, although pricing will be sensitive to local reimbursement policies.
References
- IQVIA. (2022). Global migraine market report. Retrieved from https://www.iqvia.com
- U.S. Food and Drug Administration. (2020). Vyepti (Eptinezumab) prescribing information. Retrieved from https://www.fda.gov
- IMS Health. (2022). Biologic treatment landscape report.
[1] U.S. Food and Drug Administration. (2020). Vyepti (Eptinezumab) prescribing information.
